• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Acadia is hiring and looking strongly at Sage recruits

anonymous

Guest
Long term care specialist openings. I'm on my second virtual interview. Looks very good. I was told pay range for base would be 145k to high 160's, 45K bonus at target. The manager interviewing me was very nice and they seem to have a good working culture there. Openings all over the country. They seem to be targeting Sage Therapeutic reps. It would be a great fit.
 












Sagesters: Be careful with this company! Selling high-priced meds in the nursing home setting is fraught with failure. Generics (e.g., valium, xanax, depacote, etc.) are the preferred CNS drugs for patients. Price does matter. Could be Sage Part II.
 








Sagesters: Be careful with this company! Selling high-priced meds in the nursing home setting is fraught with failure. Generics (e.g., valium, xanax, depacote, etc.) are the preferred CNS drugs for patients. Price does matter. Could be Sage Part II.

Listen, anything is a risk in this industry. I don't agree with your other comment. It is a good company. Good leadership. I say it is a good one to look at!
 
















This topic irritates me. As though “Sage Recruits” are that special...you all got lucky for a brief moment in time getting a high salary. So I guess that is what made you all special?
 




This topic irritates me. As though “Sage Recruits” are that special...you all got lucky for a brief moment in time getting a high salary. So I guess that is what made you all special?

Listen...we aren't all pricks that came from Sage. So please try not to generalize when you make the comments. Not sure where you came from thought, but their salaries sucked in my opinion.
 




Listen...we aren't all pricks that came from Sage. So please try not to generalize when you make the comments. Not sure where you came from thought, but their salaries sucked in my opinion.[/QUOTE

From what I have seen base may be a bit lower but incentive target is a bit more. So if you are good you should have no trouble making it up in incentive dollars. And to be really honest if you are an ex Sagean out of work you are
Not operating from a position of strength. Wake up and smell the coffee. Jobs are scarce right now and competition is fierce
As
Many people
Are out of work. Check the ego and good
Luck to all
 

















You are a total asshole. Yes the MDD trail did not turn out well and the company will not pursue further studies. Happens all the time. However, that has nothing to do with the NDA filed for ALZ Psychosis which will be approved and offers huge potential to help patients and generate revenue. So please crawl back under the rock your crawled out from under and go fuck yourself. Cheers!
 




You are a total asshole. Yes the MDD trail did not turn out well and the company will not pursue further studies. Happens all the time. However, that has nothing to do with the NDA filed for ALZ Psychosis which will be approved and offers huge potential to help patients and generate revenue. So please crawl back under the rock your crawled out from under and go fuck yourself. Cheers!
Sorry for putting a damper on Acadia but ALZ psychosis is already being treated with generic benzos, Depakote, lithium, etc. Selling in a long term care institution is almost impossible! Formularies are based on COST.
 




Sorry for putting a damper on Acadia but ALZ psychosis is already being treated with generic benzos, Depakote, lithium, etc. Selling in a long term care institution is almost impossible! Formularies are based on COST.

Take another hit off the pipe and swig out of your bottle. Those same meds could be used to treat Parkinson’s Delusions and Psychosis. Somehow Acadia has managed to seek in excess of $350M for that one indication. No reason they won’t be successful with the larger ALZ indication. If your argument had merit then there would be nothing but generic utilization in the psych market and we know that’s not the case.
 








Take another hit off the pipe and swig out of your bottle. Those same meds could be used to treat Parkinson’s Delusions and Psychosis. Somehow Acadia has managed to seek in excess of $350M for that one indication. No reason they won’t be successful with the larger ALZ indication. If your argument had merit then there would be nothing but generic utilization in the psych market and we know that’s not the case.
There is a large NIH study underway evaluating the use of lithium in ALZ psychosis. Beware of the market dynamics in nursing home environment. Best of luck to my Sagesters.